[January 13, 2015]

Bertech Diagnostics Ltd Licenses The Lung Cancer Test™ for the Canadian Market

Bertech Diagnostics Ltd. announced the signing of a license agreement with Global Cancer Diagnostics of Tempe, Arizona. This agreement enables Bertech to sell The Lung Cancer Test^TM in Canada. With this partnership The Lung Cancer Test^TM will continue its rapid expansion for use by current and former smokers. The Lung Cancer Test was introduced to the U.S. marketplace in late 2014.

The Lung Cancer Test^TM can be utilized for annual screening for Lung Cancer in current and former smokers. The Test has been clinically proven to detect Lung Cancer in its early stages. With early detection comes early treatment and higher survival rates.

Bertech is addressing the need for patient-friendly, accurate and inexpensive diagnostic tests in Canada. They are located in Edmonton, Alberta and will utilize partnerships with laboratories throughout Canada to provide the test to Canadians. The Lung Cancer Test™ will be a complement to Bertech's line of colorectal cancer diagnostics and treatments. Information on The Lung Cancer Test^TM in Canada can be obtained by contacting Bertech at [email protected].

All required Clinical and Validation studies have been completed with excellent results. The Test detects the presence of the required biomarkers that are proven effective in the early detection of lung cancer. The Test is now available in all U.S. states. The Lung Cancer Test™ is intended for use in the high-risk patient population which inclues current and former smokers over the age of 50. Global Cancer Diagnostics Inc. announced that The Lung Cancer Test was available for purchase beginning late last year.

More information in the U.S. can be obtained at www.TheLungCancerTest.com or by calling the Global Cancer Diagnostics laboratory at (602) 908-9604. The website provides information on lung cancer, how the test works, along with corporate management bios.

About Lung Cancer

Lung cancer is the most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the leading cause of death from cancer for both men and women in Canada. In 2014 it was estimated that 26,100 Canadians would be diagnosed with lung cancer which represents 14% of all new cancer cases in 2014 and 20,500 Canadians would die from lung cancer which represents 27% of all cancer deaths in 2014. There are approximately 5.7M Canadians who smoke and of these, there are approximately 2.0M Canadians over the age of 50 that would benefit from the immunoassay to screen for Lung Cancer to significantly improve survivability rates.

About Bertech Diagnostics Ltd:

Bertech Diagnostics Ltd. ("Bertech") is a privately held biotechnology company located in Edmonton, Canada. Bertech and its affiliated enterprises ("The Bertech Group") develop and distribute innovative, leading edge tools for the diagnosis and treatment of cancer.

In addition to ensuring the Canadian market has access to Global Cancer Diagnostic's innovative The Lung Cancer Test™, Bertech currently has in development a novel blood test for the diagnosis of colorectal cancer, an ELISA assay for monitoring a patient's immune response to colorectal cancer treatments, along with several new cancer compounds which are in preclinical development. These compounds are structurally divergent from established drugs, are devoid of the genotoxic properties of many contemporary anti-cancer drugs, and will reverse multi-drug resistance.

About Global Cancer Diagnostics Inc.

Global Cancer Diagnostics is a privately owned, Biotechnology Company with an in-house CLIA certified diagnostic laboratory. The Company is located in Tempe, Arizona USA. The Company provides the scientific and operating management resources to have introduced its novel diagnostic technology in the domestic and global marketplace. For more information, visit the company's Web site at www.TheLungCancerTest.com.

[ Back To TMCnet.com's Homepage ]